dc.contributor.author |
Martínez Bosch, Neus |
dc.contributor.author |
Alameda Quitllet, Francisco |
dc.contributor.author |
Arumí Uría, Montserrat |
dc.contributor.author |
Bellosillo Paricio, Beatriz |
dc.contributor.author |
Menéndez, Silvia |
dc.contributor.author |
Esteve-Codina, Anna |
dc.contributor.author |
Martínez-García, Maria |
dc.contributor.author |
Navarro Medrano, Pilar |
dc.date.accessioned |
2023-06-15T06:00:25Z |
dc.date.available |
2023-06-15T06:00:25Z |
dc.date.issued |
2023 |
dc.identifier.citation |
Martínez-Bosch N, Vilariño N, Alameda F, Mojal S, Arumí-Uria M, Carrato C, et al. Gal-1 expression analysis in the GLIOCAT multicenter study: Role as a prognostic factor and an immune-suppressive biomarker. Cells. 2023 Mar 8;12(6):843. DOI: 10.3390/cells12060843 |
dc.identifier.issn |
2073-4409 |
dc.identifier.uri |
http://hdl.handle.net/10230/57171 |
dc.description.abstract |
Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The β-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4 IDH-1 mutant astrocytomas, which have a better prognosis. Our results confirm the role of Gal-1 as a prognostic factor and also suggest its value as an immune-suppressive biomarker in GBM. |
dc.format.mimetype |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
MDPI |
dc.relation.ispartof |
Cells. 2023 Mar 8;12(6):843 |
dc.rights |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
dc.rights.uri |
http://creativecommons.org/licenses/by/4.0/ |
dc.title |
Gal-1 expression analysis in the GLIOCAT multicenter study: Role as a prognostic factor and an immune-suppressive biomarker |
dc.type |
info:eu-repo/semantics/article |
dc.identifier.doi |
http://dx.doi.org/10.3390/cells12060843 |
dc.subject.keyword |
Galectin-1 |
dc.subject.keyword |
IDH-1 |
dc.subject.keyword |
Glioblastoma |
dc.subject.keyword |
Immune-suppression |
dc.subject.keyword |
Mesenchymal molecular subtype |
dc.subject.keyword |
Prognostic factor |
dc.rights.accessRights |
info:eu-repo/semantics/openAccess |
dc.type.version |
info:eu-repo/semantics/publishedVersion |